PACB
Pacific Biosciences of California, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.35
+3.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 159.3M | 160.0M | 154.0M | 200.5M | 128.3M |
| Cost of Revenue | 102.0M | 109.3M | 116.7M | 147.7M | 79.3M |
| Gross Profit | 57.3M | 50.7M | 37.3M | 52.8M | 49.0M |
| Operating Expenses | |||||
| R&D Expense | 88.4M | 97.3M | 134.9M | 187.2M | 193.0M |
| SG&A Expense | 129.7M | 141.5M | 175.0M | 169.8M | 160.9M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.8M | 369.4M | 201.7M | 30.3M | 2.4M |
| Total Operating Expenses | 219.8M | 608.2M | 511.6M | 387.2M | 356.2M |
| Cost and Expenses | 321.8M | 717.6M | 628.3M | 535.0M | 435.5M |
| Operating Income (EBIT) | (162.5M) | (557.6M) | (474.3M) | (334.5M) | (307.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 3.8M | 7.0M | 13.4M | 14.3M | 14.7M |
| Net Interest Income | (3.8M) | (7.0M) | (13.4M) | (14.3M) | (14.7M) |
| Other Non-Op Income/Expense | 32.0M | 11.5M | 164.8M | 16.3M | (7.1M) |
| Non-Operating Income (excl Interest) | (35.8M) | (18.5M) | (178.2M) | (30.7M) | (7.6M) |
| EBT (Pre-Tax Income) | (130.6M) | (546.1M) | (309.5M) | (318.2M) | (314.2M) |
| Income Tax Expense | 827.0K | 318.0K | 316.0K | (11.4M) | — |
| Bottom Line | |||||
| Net Income | (131.4M) | (546.4M) | (309.9M) | (306.7M) | (314.2M) |
| Earnings from Cont. Ops | (131.4M) | (546.4M) | (309.9M) | (306.7M) | (314.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (131.4M) | (546.4M) | (309.9M) | (306.7M) | (314.2M) |
| Per Share | |||||
| Basic EPS | ($0.43) | ($1.82) | ($1.13) | ($1.21) | ($1.40) |
| Diluted EPS | ($0.43) | ($1.82) | ($1.07) | ($1.21) | ($1.40) |
| Revenue Per Share | $0.51 | $0.53 | $0.56 | $0.79 | $0.57 |
| Shares | |||||
| Basic Shares Outstanding | 310.7M | 300.0M | 274.5M | 253.6M | 224.6M |
| Diluted Shares Outstanding | 310.7M | 300.0M | 288.4M | 253.6M | 224.6M |
| Profitability Metrics | |||||
| EBITDA | (109.1M) | (34.2M) | (242.8M) | (271.1M) | (282.2M) |
| D&A | 17.6M | 504.9M | 53.4M | 32.7M | 17.3M |
| EBIT | (126.7M) | (539.1M) | (296.1M) | (303.8M) | (299.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026